Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Sangamo Therapeutics (SGMO) Leases (2019 - 2025)

Sangamo Therapeutics has reported Leases over the past 7 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Leases at $3.1 million for Q4 2025, down 81.84% from a year ago — trailing twelve months through Dec 2025 was $3.1 million (down 81.84% YoY), and the annual figure for FY2025 was $3.1 million, down 81.84%.
  • Leases for Q4 2025 was $3.1 million at Sangamo Therapeutics, down from $14.4 million in the prior quarter.
  • Over the last five years, Leases for SGMO hit a ceiling of $73.2 million in Q4 2021 and a floor of $3.1 million in Q4 2025.
  • Median Leases over the past 5 years was $37.0 million (2023), compared with a mean of $40.8 million.
  • Biggest five-year swings in Leases: rose 3.01% in 2021 and later tumbled 81.84% in 2025.
  • Sangamo Therapeutics' Leases stood at $73.2 million in 2021, then decreased by 15.28% to $62.0 million in 2022, then crashed by 58.08% to $26.0 million in 2023, then plummeted by 35.1% to $16.9 million in 2024, then tumbled by 81.84% to $3.1 million in 2025.
  • The last three reported values for Leases were $3.1 million (Q4 2025), $14.4 million (Q3 2025), and $15.1 million (Q2 2025) per Business Quant data.